Sökning: WFRF:(Burska A) >
2022 EULAR points t...
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
-
- Rodriguez-Carrio, Javier (författare)
- Univ Oviedo, Dept Funct Biol, Inst Invest Sanitaria Principado Asturias ISPA, Asturias, Spain.
-
- Burska, Agata (författare)
- Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England.;NIHR Leeds Biomed Res Ctr, Leeds, England.
-
- Conaghan, Philip G. (författare)
- Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England.;NIHR Leeds Biomed Res Ctr, Leeds, England.
-
visa fler...
-
- Dik, Willem A. (författare)
- Univ Med Ctr Rotterdam, Dept Immunol, Lab Med Immunol, Erasmus MC, Rotterdam, Netherlands.
-
- Biesen, Robert (författare)
- Charite Univ Med Berlin, Dept Rheumatol, Berlin, Germany.
-
- Eloranta, Maija-Leena (författare)
- Uppsala universitet,Reumatologi
-
- Cavalli, Giulio (författare)
- Univ Vita Salute San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis, Milan, Italy.
-
- Visser, Marianne (författare)
- EULAR PARE Patient Res Partner, Amsterdam, Netherlands.
-
- Boumpas, Dimitrios T. (författare)
- Univ Crete, Med Sch, Dept Internal Med, Med, Iraklion, Greece.
-
- Bertsias, George (författare)
- Univ Crete, Sch Med, Dept Rheumatol Clin Immunol, Iraklion, Greece.
-
- Wahren-Herlenius, Marie (författare)
- Karolinska Institutet,Karolinska Inst, Div Rheumatol, Stockholm, Sweden.;Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, Bergen, Norway.
-
- Rehwinkel, Jan (författare)
- Univ Oxford, Weatherall Inst Mol Med, Human Immunol Unit, Radcliffe Dept Med,Med Res Council, Oxford, England.
-
- Fremond, Marie-Louise (författare)
- Univ Paris Cite, Hop Necker Enfants Malad, Immuno Hematol & Rhumatol Pediat, Paris, France.
-
- Crow, Mary K. (författare)
- Weill Cornell Med Coll, Hosp Special Surg, Mary Kirkland Ctr Lupus Res, New York, NY USA.
-
- Rönnblom, Lars (författare)
- Uppsala universitet,Reumatologi
-
- Versnel, Marjan A. (författare)
- Univ Med Ctr Rotterdam, Dept Immunol, Erasmus MC, Rotterdam, Netherlands.
-
- Vital, Edward M. (författare)
- Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England.;NIHR Leeds Biomed Res Ctr, Leeds, England.
-
visa färre...
-
Univ Oviedo, Dept Funct Biol, Inst Invest Sanitaria Principado Asturias ISPA, Asturias, Spain Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England.;NIHR Leeds Biomed Res Ctr, Leeds, England. (creator_code:org_t)
- 2023-03-01
- 2023
- Engelska.
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ Publishing Group Ltd. - 0003-4967 .- 1468-2060. ; 82:6, s. 754-762
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Type I interferons (IFN-Is) play a role in a broad range of rheumatic and musculoskeletal diseases (RMDs), and compelling evidence suggests that their measurement could have clinical value, although testing has not progressed into clinical settings.Objective: To develop evidence-based points to consider (PtC) for the measurement and reporting of IFN-I assays in clinical research and to determine their potential clinical utility.Methods: EULAR standardised operating procedures were followed. A task force including rheumatologists, immunologists, translational scientists and a patient partner was formed. Two systematic reviews were conducted to address methodological and clinical questions. PtC were formulated based on the retrieved evidence and expert opinion. Level of evidence and agreement was determined.Results: Two overarching principles and 11 PtC were defined. The first set (PtC 1-4) concerned terminology, assay characteristics and reporting practices to enable more consistent reporting and facilitate translation and collaborations. The second set (PtC 5-11) addressed clinical applications for diagnosis and outcome assessments, including disease activity, prognosis and prediction of treatment response. The mean level of agreement was generally high, mainly in the first PtC set and for clinical applications in systemic lupus erythematosus. Harmonisation of assay methodology and clinical validation were key points for the research agenda.Conclusions: IFN-I assays have a high potential for implementation in the clinical management of RMDs. Uptake of these PtC will facilitate the progress of IFN-I assays into clinical practice and may be also of interest beyond rheumatology.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Nyckelord
- systemic lupus erythematosus
- rheumatoid arthritis
- polymyositis
- systemic sclerosis
- cytokines
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Rodriguez-Carrio ...
-
Burska, Agata
-
Conaghan, Philip ...
-
Dik, Willem A.
-
Biesen, Robert
-
Eloranta, Maija- ...
-
visa fler...
-
Cavalli, Giulio
-
Visser, Marianne
-
Boumpas, Dimitri ...
-
Bertsias, George
-
Wahren-Herlenius ...
-
Rehwinkel, Jan
-
Fremond, Marie-L ...
-
Crow, Mary K.
-
Rönnblom, Lars
-
Versnel, Marjan ...
-
Vital, Edward M.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Reumatologi och ...
- Artiklar i publikationen
-
Annals of the Rh ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet